1-3 of 3
Radosław Mlak
Close
Sort by
Journal Articles

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

Malgorzata Zajac, PhD, Joanna Zaleska, Anna Dolnik, PhD, Anna Siwiec, PhD, Olga Jankowska-Lecka, PhD, Radoslaw Mlak, PhD, Marzanna Ciesielka, PhD, Tomasz Gromek, MD PhD, Bozena Sokolowska, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Maria Majdan, MD, Marek Hus, MD PhD, Lars Bullinger, MD, Krzysztof Giannopoulos, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1685.
https://doi.org/10.1182/blood.V128.22.1685.1685
Published: 2016
Journal Articles

Uncovering Thalidomide Mechanism of Action: Neuropilin 1 Represents the Target of Antiangiogenic and Immunomodulatory Effect in Chronic Lymphocytic Leukemia

Krzysztof Giannopoulos, MD, PhD, Marcin Omiotek, Kamila Kosior, Radoslaw Mlak, Malgorzata Kowal, Jacek M. Rolinski, Hartmut Dohner, MD, Stephan Stilgenbauer, MD, Anna Dmoszynska, Lars Bullinger
Journal: Blood
Blood (2011) 118 (21): 4608.
https://doi.org/10.1182/blood.V118.21.4608.4608
Published: 2011
Journal Articles

Neuropilin-1 – Novel, Promising Target for Chronic Lymphocytic Leukemia patients.

Krzysztof Giannopoulos, Marcin Omiotek, Radosław Mlak, Waldemar Tomczak, Jacek M. Rolinski, Anna Dmoszynska, Stephan Stilgenbauer, MD, Lars Bullinger
Journal: Blood
Blood (2009) 114 (22): 4392.
https://doi.org/10.1182/blood.V114.22.4392.4392
Published: 2009